Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors

Mise à jour : Il y a 5 ans
Référence : NCT00951405

Extrait

This trial is conducted in Asia, Europe, Japan and North America. The aim of this clinical trial is to investigate the safety and the efficacy of a prophylactic treatment option with long acting coagulation factor VII (LA-rFVIIa) for haemophilia patients with inhibitors.


Critère d'inclusion

  • Congenital Bleeding Disorder ,Haemophilia A With Inhibitors ,Haemophilia B With Inhibitors


Liens